1.
Levin WP, Kooy H, Loeffler JS, et al. Proton beam therapy. Br J Cancer. 2005;93:849–54. [PMC free article: PMC2361650] [PubMed: 16189526]
2.
Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9:367–75. [PubMed: 18374290]
3.
Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407–21. [PubMed: 12023146]
4.
Matsufuji N, Kanai T, Kanematsu N, et al. Specification of Carbon Ion Dose at the National Institute of Radiological Sciences (NIRS) J Radiat Res (Tokyo) 2007;48( Suppl A):A81–A86. [PubMed: 17513903]
5.
EpiData (version 3). A comprehensive tool for validated entry and documentation of data. The EpiData Association, Odense Denmark [computer program]. Version 3.1 2004.
6.
Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–64. [PubMed: 17350944]
7.
Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–70. [PubMed: 17350945]
8.
Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297:2705–15. [PubMed: 17595271]
9.
Goitein M. Magical protons? Int J Radiat Oncol Biol Phys. 2008;70:654–6. [PubMed: 18262083]
10.
Gueulette J, Wambersie A. Comparison of the Methods of Specifying Carbon Ion Doses at NIRS and GSI. J Radiat Res (Tokyo) 2007;48( Suppl A):A97–A102. [PubMed: 17513905]
11.
Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol. 2006;24:2618–23. [PubMed: 16763274]
12.
Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–44. [PubMed: 18091059]
13.
Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25:947–52. [PubMed: 17350943]
14.
Patel RR, Arthur DW. The emergence of advanced brachytherapy techniques for common malignancies. Hematol Oncol Clin North Am. 2006;20:97–118. [PubMed: 16580559]
15.
Sisterson J. Treatment planning systems for proton and ion beam therapy. Particles. 2005;10
16.
Benk V, Liebsch NJ, Munzenrider JE, et al. Base of skull and cervical spine chordomas in children treated by high-dose irradiation. International Journal of Radiation Oncology, Biology, Physics. 1995;31(3):577–81. [PubMed: 7852123]
17.
Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. International Journal of Radiation Oncology, Biology, Physics. 1999;45(5):1117–26. [PubMed: 10613303]
18.
Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlentherapie und Onkologie. 2002;178(1):10–7. [PubMed: 11977386]
19.
Hug EB, Sweeney RA, Nurre PM, et al. Proton radiotherapy in management of pediatric base of skull tumors. International Journal of Radiation Oncology, Biology, Physics. 2002;52(4):1017–24. [PubMed: 11958897]
20.
McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. International Journal of Radiation Oncology, Biology, Physics. 1997;39(2):455–60. [PubMed: 9308950]
21.
Noel G, Habrand JL, Helfre S, et al. Proton beam therapy in the management of central nervous system tumors in childhood: the preliminary experience of the Centre de Protontherapie d'Orsay. Medical & Pediatric Oncology. 2003;40(5):309–15. [PubMed: 12652619]
22.
Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. International Journal of Radiation Oncology, Biology, Physics. 2007;67(2):497–504. [PubMed: 17084557]
23.
Bush DA, Dunbar RD, Bonnet R, et al. Pulmonary injury from proton and conventional radiotherapy as revealed by CT. AJR American Journal of Roentgenology. 1999;172(3):735–9. [PubMed: 10063871]
24.
Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999;116(5):1313–9. [PubMed: 10559093]
25.
Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126(4):1198–203. [PubMed: 15486383]
26.
Bonnet RB, Bush D, Cheek GA, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest. 2001;120(6):1803–10. [PubMed: 11742905]
27.
Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. International Journal of Radiation Oncology, Biology, Physics. 2007;68(3):786–93. [PubMed: 17379439]
28.
Kozak KR, Smith BL, Adams J, et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. International Journal of Radiation Oncology, Biology, Physics. 2006;66(3):691–8. [PubMed: 17011445]
29.
Miyamoto T, Baba M, Sugane T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week [see comment] Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2007;2(10):916–26. [PubMed: 17909354]
30.
Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. International Journal of Radiation Oncology, Biology, Physics. 2007;67(3):750–8. [PubMed: 17293232]
31.
Hirasawa N, Tsuji H, Ishikawa H, et al. Risk factors for neovascular glaucoma after carbon ion radiotherapy of choroidal melanoma using dose-volume histogram analysis. International Journal of Radiation Oncology, Biology, Physics. 2007;67(2):538–43. [PubMed: 17141971]
32.
Tsuji H, Ishikawa H, Yanagi T, et al. Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a Phase I/II dose-escalation study. International Journal of Radiation Oncology, Biology, Physics. 2007;67(3):857–62. [PubMed: 17161555]
33.
Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial [see comment] JAMA. 2005;294(10):1233–9. [PubMed: 16160131]
34.
Char DH, Kroll S, Quivey JM, Castro J. Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation vs brachytherapy. British Journal of Ophthalmology. 1996;80(2):117–24. [PMC free article: PMC505401] [PubMed: 8814740]
35.
Desjardins L, Lumbroso L, Levy C, et al. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates] [French] Journal Francais d Opthalmologie. 2003;26(3):269–76. [PubMed: 12746603]
36.
Harbour JW, Char DH, Kroll S, et al. Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology. 1997;104(11):1785–92. discussion 1792–3. [PubMed: 9373108]
37.
Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97(6):769–77. [PubMed: 2374681]
38.
Char DH, Bove R, Phillips TL. Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. American Journal of Ophthalmology. 2003;136(1):180–2. [PubMed: 12834689]
39.
Duttenhaver JR, Shipley WU, Perrone T, et al. Protons or megavoltage X-rays as boost therapy for patients irradiated for localized prostatic carcinoma. An early phase I/II comparison. Cancer. 1983;51(9):1599–604. [PubMed: 6299503]
40.
Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncology Nursing Forum. 2001;28(3):551–60. [PubMed: 11338762]
41.
Nakano T, Suzuki Y, Ohno T, et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clinical Cancer Research. 2006;12(7 Pt 1):2185–90. [PubMed: 16609033]
42.
Schoenthaler R, Castro JR, Petti PL, et al. Charged particle irradiation of sacral chordomas. International Journal of Radiation Oncology, Biology, Physics. 1993;26(2):291–8. [PubMed: 8491686]
43.
Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Annals of Surgery. 1994;219(3):267–74. [PMC free article: PMC1243134] [PubMed: 8147607]
44.
Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104(2):338–44. [PubMed: 15937907]
45.
Seddon JM, Gragoudas ES, Albert DM, et al. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. American Journal of Ophthalmology. 1985;99(3):282–90. [PubMed: 2983558]
46.
Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology. 1999;106(8):1579–87. [PubMed: 10442907]
47.
Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Archives of Ophthalmology. 2000;118(6):773–8. [PubMed: 10865313]
48.
Char DH, Castro JR, Quivey JM, et al. Uveal melanoma radiation. 125I brachytherapy vs helium ion irradiation. Ophthalmology. 1989;96(12):1708–15. [PubMed: 2695875]
49.
Char DH, Quivey JM, Castro JR, et al. Helium ions vs iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100(10):1547–54. [PubMed: 8414414]
50.
Desjardins L, Lumbroso-Le RL, Levy-Gabriel C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients [see comment] Ophthalmic Research. 2006;38(5):255–60. [PubMed: 16888407]
51.
Santoni R, Liebsch N, Finkelstein DM, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. International Journal of Radiation Oncology, Biology, Physics. 1998;41(1):59–68. [PubMed: 9588918]
52.
Castro JR, Phillips TL, Prados M, et al. Neon heavy charged particle radiotherapy of glioblastoma of the brain. International Journal of Radiation Oncology, Biology, Physics. 1997;38(2):257–61. [PubMed: 9226311]
53.
Linstadt D, Quivey JM, Castro JR, et al. Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas. Final report of a Northern California Oncology Group randomized prospective clinical trial. Radiology. 1988;168(1):261–4. [PubMed: 3132732]
54.
Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone [see comment] International Journal of Radiation Oncology, Biology, Physics. 1995;32(1):3–12. [PubMed: 7721636]
55.
Benk VA, Adams JA, Shipley WU, et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3–T4 prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics. 1993;26(3):551–7. [PubMed: 8514551]
56.
Schoenthaler R, Castro JR, Halberg FE, et al. Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons. International Journal of Radiation Oncology, Biology, Physics. 1993;27(1):75–82. [PubMed: 8365945]
57.
Weber DC, Rutz HP, Bolsi A, et al. Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience. International Journal of Radiation Oncology, Biology, Physics. 2007;69(3):865–71. [PubMed: 17606333]
58.
Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for aged patients with hepatocellular carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2007;69(3):805–12. [PubMed: 17524568]
59.
Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–5. [PubMed: 3600702]
60.
Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol. 2008;26:175–6. [PubMed: 18182658]
61.
Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836–49. [PubMed: 16332591]
62.
D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81. [PubMed: 9802183]
63.
Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278–85. [PMC free article: PMC2170524] [PubMed: 17227979]
64.
Wilt TJ, Shamliyan T, Taylor B, et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer Comparative Effectiveness Review No. 13. Rockville, MD: Agency for Healthcare Research and Quality; 2008. (Prepared by Minnesota Evidence-based Practice Center under Contract No. 290-02-00009.)
65.
Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435–48. [PubMed: 18252677]